Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| ABZ1618-100 | 2 weeks | 100 µL | $499.00 |
Select product before adding to cart
|
||
| ABZ1618-20 | 2 weeks | 20 µL | $149.00 |
Product Overview | |
| Name | KIR2DL2/3 Rabbit pAb |
|---|---|
| Accession (Primary) | P43628 |
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Species Reactivity | |
| Reacts With | Human |
| Calculated MW | |
| Calculated MW: 38 kDa; Observed MW: 38 kDa | |
| Buffer System | |
| Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3. | |
| Storage | |
| Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. | |
| Recommended Dilution | |
| WB-1:500-1:2000; ELISA-1:20000 | |
| Purification | |
| Affinity Purified | |
| Conjugation | |
| Unconjugated | |
| Modification | |
| Unmodified | |
| Form | |
| Liquid | |
| Background | |
| Killer cell immunoglobulin-like receptors (KIRs) are a diverse family of inhibitory and activating receptors expressed on NK cells and a subset of T cells (PMID: 11861603). These polymorphic receptors interact with specific motifs on HLA class I molecules, modulate NK cytolytic activity and are encoded by genes located on chromosome 19q13. 4 (PMID: 17069649). KIR2DL3, also known as CD158B2 or NKAT2, is an inhibitory receptor that is specific for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7) (PMID: 10196125). It is a 341-amino acid transmembrane glycoprotein consisting of an extracellular region containing two C2-type Ig-like domains, a 19-amino acid hydrophobic transmembrane region, and a long cytoplasmic tail with two immunoreceptor tyrosine-based inhibitory motifs (ITIMs). KIR2DL3 inhibits the cytolytic activity of NK cells thus preventing cell lysis (PMID: 7724594). KIR2DS2 is associated with reduced post-transplant recurrence and improved prognosis in solid tumors of hematologic malignancies and is an attractive target for NK-based therapeutic strategies. Furthermore, KIR2DS2 is associated with increased activation of anti-glioblastoma cells and improved clinical responses in breast, colorectal, non-small cell lung and hepatocellular carcinomas. (PMID: 35768150) Currently KIR2DS2 has been shown to directly recognize viral deconjugating peptides in the context of HLA-C and is protective against chronic hepatitis C virus infection. The high sequence homology between KIR2DS2 and inhibitory KIRs (KIR2DL2 and KIR2DL3) has made it difficult to develop an antibody that specifically detects KIR2DS2. | |
Target Information: ( P43628 ) | |
| Name | KIR2DL3/KIR2DS2 |
| Gene ID | 3804/100132285 |
| Other Names | |
| KIR2DL3; CD158B2; KIRCL23; NKAT2; Killer cell immunoglobulin-like receptor 2DL3; CD158 antigen-like family member B2; KIR-023GB; Killer inhibitory receptor cl 2-3; MHC class I NK cell receptor; NKAT2a; NKAT2bNatural killer-associated transcript 2; NKAT-2; p58 natural killer cell receptor clone CL-6; p58 NK receptor CL-6; p58.2 MHC class-I-specific NK receptor; CD158b2; KIR2DS2; CD158J; NKAT5; Killer cell immunoglobulin-like receptor 2DS2 | |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
